KRTX and PRTC Related Headlines
Go Back- PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
- PureTech Health Plc (PRTC) Issues Year End Update and Outlook for 2024
- PureTech Year End Update and Outlook for 2024
- PureTech Health (PRTC) Founded Entity Karuna Therapeutics (KRTX) Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
- PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
- PureTech Health (PRTC) Reports Karuna's (KRTX) Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
- PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
- PureTech to Present at Two Upcoming Investor Conferences
- KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
- PureTech Health plc – Half-Year Report
- PureTech Announces Annual Results for Year Ended December 31, 2022
KRTX and PRTC Related Press Releases
Go Back- PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
- PureTech Year End Update and Outlook for 2024
- PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
- PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
- PureTech to Present at Two Upcoming Investor Conferences
- KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
- PureTech Health plc – Half-Year Report
- PureTech Announces Annual Results for Year Ended December 31, 2022